These results align with findings by Gubin et al. (2018), who demonstrated that combination treatment of anti-CTLA-4 and anti-PD-1 remodels TAMs to a less immunosuppressive phenotype in the MCA sarcoma model. Here, CTLA4 is linked to sarcoma.